Medpace Holdings, Inc. $MEDP Shares Acquired by Global Financial Private Client LLC

Key Points

• Global Financial Private Client LLC significantly increased its stake in Medpace Holdings, Inc. by acquiring an additional 1,364 shares, resulting in a total holding of 1,418 shares valued at approximately $445,000.
• Medpace reported earnings of $3.10 per share for the last quarter, exceeding analyst expectations, and highlighted a revenue increase of 14.2% year-over-year.
• Insider selling activity was noted, with Director Cornelius P. McCarthy III and VP Susan E. Burwig both reducing their shareholdings amidst a total of 161,266 shares sold by insiders over the last quarter.

Global Financial Private Client LLC grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 2,525.9% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 1,418 shares of the company's stock after buying an additional 1,364 shares during the period. Global Financial Private Client LLC's holdings in Medpace were worth $445,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Whittier Trust Co. raised its holdings in shares of Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after buying an additional 35 shares during the last quarter. Benjamin Edwards Inc. increased its stake in shares of Medpace by 3.1% during the first quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company's stock worth $366,000 after acquiring an additional 36 shares during the period. Geneos Wealth Management Inc. increased its stake in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after acquiring an additional 37 shares during the period. Assetmark Inc. increased its stake in shares of Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after acquiring an additional 43 shares during the period. Finally, Proficio Capital Partners LLC increased its stake in shares of Medpace by 6.4% during the first quarter. Proficio Capital Partners LLC now owns 777 shares of the company's stock worth $237,000 after acquiring an additional 47 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Rothschild & Co Redburn lowered shares of Medpace from a "buy" rating to a "neutral" rating and boosted their price target for the stock from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Cowen lowered shares of Medpace from a "buy" rating to a "sell" rating in a research note on Wednesday, July 23rd. Rothschild Redb lowered shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 3rd. Robert W. Baird boosted their price target on shares of Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Finally, UBS Group lowered shares of Medpace from a "neutral" rating to a "sell" rating and boosted their price target for the stock from $300.00 to $305.00 in a research note on Tuesday, July 29th. Two analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Reduce" and an average price target of $422.27.

Insiders Place Their Bets

In other news, CFO Kevin M. Brady sold 12,000 shares of the stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total value of $5,450,760.00. Following the sale, the chief financial officer directly owned 6,000 shares in the company, valued at $2,725,380. This represents a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Cornelius P. Mccarthy III sold 1,662 shares of the stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $465.04, for a total transaction of $772,896.48. Following the completion of the sale, the director owned 10,197 shares in the company, valued at $4,742,012.88. This represents a 14.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 161,266 shares of company stock valued at $74,111,427. Corporate insiders own 20.30% of the company's stock.

Medpace Stock Performance

MEDP traded down $0.52 on Monday, hitting $498.08. 155,854 shares of the company were exchanged, compared to its average volume of 316,492. The business's fifty day moving average is $450.44 and its 200 day moving average is $356.61. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $506.55. The firm has a market capitalization of $13.99 billion, a P/E ratio of 37.03, a price-to-earnings-growth ratio of 3.14 and a beta of 1.44.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. During the same period in the prior year, the business posted $2.75 earnings per share. The firm's revenue for the quarter was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.